PMID- 37936126 OWN - NLM STAT- MEDLINE DCOM- 20231115 LR - 20231115 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Nov 7 TI - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: the CHAMP study. PG - 1074 LID - 10.1186/s12885-023-11562-2 [doi] LID - 1074 AB - BACKGROUND: There is still a profound lack of efficient therapeutic strategies against pancreatic and other periampullary adenocarcinoma. Surgery is seldom possible, leaving palliative chemotherapy the only option for most patients. Chemotherapy treatment is however often accompanied by serious side-effects, and the identification of biomarkers for early prediction of disease and treatment-associated symptoms could help alleviate patient suffering. This study investigated the dynamic interrelationship between immune-related serum proteins, routine biomarkers, and health-related quality of life (HRQoL) factors during chemotherapy treatment of patients enrolled in the prospective, observational study Chemotherapy, Host response And Molecular dynamics in Periampullary cancer (CHAMP). METHODS: Proximity extension assay was applied to analyse 92 immune-associated proteins in longitudinal serum samples from 75 patients, 18 treated with curative and 57 with palliative intent. HRQoL data were available from all patients at baseline (BL), from 41 patients at three months, and from 23 patients at six months. Information on routine laboratory parameters albumin, CA19-9, CEA and CRP were collected from medical charts. RESULTS: In total nine proteins; chemokine (C-C motif) ligand 23 (CCL23), cluster of differentiation 4 (CD4), cluster of differentiation 28 (CD28), decorin (DCN), galectin-1 (Gal-1), granzyme B (GZMB), granzyme H (GZMH), matrix metallopeptidase 7 (MMP7), and monocyte chemotactic protein-1 (MCP-1) were strongly correlated (Spearman's Rho /= 0.6) with either cognitive functioning (DCN), emotional functioning (DCN, MCP-1), dyspnoea (CD28, GZMB, GZMH) or insomnia (CCL23, CD4, Gal-1, MMP7) during treatment. Associations between routine laboratory parameters (CA 19-9, CA-125, CRP, CEA and albumin) and HRQoL factors were overall weaker. None of the investigated proteins were associated with pain. CONCLUSIONS: This is, to our knowledge, the first study exploring associations between serum biomarkers and HRQoL in patients with pancreatic or other periampullary cancer, and some findings merit further validation. The associations of DCN and MCP-1with impaired cognitive and/or emotional functioning are of particular interest, given their established link to various neurodegenerative conditions. Chemotherapy is known to cause persistent cognitive dysfunction with effects on memory and executive function, referred to as "chemo brain". It would therefore be of great value to identify biomarkers for early detection and management of this debilitating condition. TRIAL REGISTRATION: Clinical Trial Registration: NCT03724994. CI - (c) 2023. The Author(s). FAU - Hau, Sofie Olsson AU - Hau SO AUID- ORCID: 0000-0002-1702-9884 AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. sofie.olsson_hau@med.lu.se. FAU - Svensson, Maja AU - Svensson M AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Petersson, Alexandra AU - Petersson A AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Eberhard, Jakob AU - Eberhard J AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Jirstrom, Karin AU - Jirstrom K AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. LA - eng SI - ClinicalTrials.gov/NCT03724994 GR - 2015-03598, 2018-02441/Vetenskapsradet/ GR - CAN2018/418, 21 1596 Pj/Cancerfonden/ PT - Journal Article PT - Observational Study DEP - 20231107 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 59921-69-6 (1-nitrohydroxyphenyl-N-benzoylalanine) RN - 0 (Albumins) RN - 0 (Blood Proteins) RN - 0 (CD28 Antigens) RN - EC 3.4.24.23 (Matrix Metalloproteinase 7) SB - IM MH - Humans MH - Albumins MH - *Ampulla of Vater/pathology MH - Blood Proteins MH - CD28 Antigens MH - *Duodenal Neoplasms/pathology MH - Matrix Metalloproteinase 7 MH - *Pancreatic Neoplasms/pathology MH - Prospective Studies MH - Quality of Life PMC - PMC10629201 OTO - NOTNLM OT - CD28 OT - Decorin OT - GZMB OT - GZMH OT - Health related quality of life OT - Immune-associated serum proteins OT - MCP-1 OT - Pancreatic cancer OT - Periampullary cancer OT - Routine biomarkers COIS- The authors declare no competing interests. EDAT- 2023/11/08 00:42 MHDA- 2023/11/09 06:42 PMCR- 2023/11/07 CRDT- 2023/11/08 00:00 PHST- 2023/07/17 00:00 [received] PHST- 2023/10/24 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/11/08 00:42 [pubmed] PHST- 2023/11/08 00:00 [entrez] PHST- 2023/11/07 00:00 [pmc-release] AID - 10.1186/s12885-023-11562-2 [pii] AID - 11562 [pii] AID - 10.1186/s12885-023-11562-2 [doi] PST - epublish SO - BMC Cancer. 2023 Nov 7;23(1):1074. doi: 10.1186/s12885-023-11562-2.